Become a New Member!

Post a Career Opportunity

List a Professional Resource

Membership Renewal


Having Trouble?

Trouble with Membership Renewal?

UPCOMING EVENTS

NCRAF's Spring Summit will have a return engagement by

Dr. Robert Califf

former FDA Commissioner

 

May 18, 2017

details to come.

 ===================== 

RAC EU online Workshop

Register for the self-paced course starting Feb. 7, 2017 

Click to see details

==========================

ECTD Group Meetings

These meetings have resumed as quarterly get togethers for 2017

Click to see details 

 ==========================

 

 

PDF Email

assets/Education/2016-02-18-regulatory_intelligence_in_drug_development.pdf 

Date Round
Table
Speaker  Speaker Affiliation Topic Link to WebEx Recording
 2016-10    Bob Rohde, Susan Sisk    Out-of-(CSR)-Body Experiences-Tips on Assembling Appendices, Datasets, and CRFs  

WEBINAR LINK:  https://quintilesconferencing.webex.com/quintilesconferencing/ldr.php?RCID=fa848ab092261d9ed31496f9317e328f

SLIDES-ROHDE LINK:   assets/Education/csr dataset-crfs-refs-final-br-10-16-2016-handout.pdf

SLIDES-SKSK LINK: assets/Education/csr appendices-datasets-crfs-2016-10-10-notes-bw.pdf

 

 2016-09   Suneela Thatte, VP, Global Operations  Quintiles India Regulatory Turnaround makes India an Increasingly Attractive Location for Clinical Research  WEBINAR LINK:  https://quintilesconferencing.webex.com/quintilesconferencing/ldr.php?RCID=fa848ab092261d9ed31496f9317e328f
2016-05   Carla Balch  President, NantCare and NantCRO  A Regulatory Overview of Cancer MoonShot2020  
2016-04-   Susan Bostian, MURP, PE Duncklee & Dunham’s Environmental Regulatory Compliance team Environmental Regulations for Destruction of Investigation Products  
2016-03-10   Jane Horvath 3D Communications

Truth & Consequences: Pricing, Patient Access and What's Next for Today's BioPharm

 
2016-02-18   Kirsten Messmer and Charity Metz Schuller

Senior RA Specialist, Regulatory Intelligence Solutions; and Director, Regulatory Affairs, PPDI

"Regulatory Intelligence" - Building Strategies for Drug Development

WEBEX:  https://quintilesconferencing.webex.com/quintilesconferencing/ldr.php?RCID=45f83246508a3513104de22017656d7f

SLIDES: assets/Education/2016-02-18-regulatory_intelligence_in_drug_development.pdf

 

2016-01-28   Rebecca Carson Rogers Chairperson, Schulman IRB

"Orphan Devices" - Humanitarian Use Device (HUD) Exemptions

 
2015-11-12 01 Brian McMerty President, Carlyle Conlan

Career Development

 
2015-11-12 02 Poonam Pande President, Integrated CMC Solutions

cGMPs and inspections: Overview from FDA's recent SBIA meeting

 
2015-11-12 03 Kevin Healy Senior Director of Regulatory Affairs, Mallinckrodt Pharmaceuticals

Bio Like Me: Recent Events & Current Hot Topics with Biosimilars

 
2015-11-12 04 Drusilla Scott Senior Vice-President, Regulatory Affairs,Cempra Pharmaceuticals

The End of Alphabet Soup – The Pregnancy and Lactation Labeling Rule

 
2015-11-12 05 Evan Richardson Director, Regulatory Submissions, GlobalSubmit, Inc.

Making a List and Checking it Twice: Using Checklists to Ensure High Quality Regulatory Submissions.

 
2015-11-12 06 BJ Witkin

Regulatory Publishing Manager, Impact Pharmaceutical Services

Who's on First?  The new Module 1  
2015-11-12 07 Elvis Osei-Tutu Post-doctoral Fellow, GlaxoSmithKline

Name that Drug! How pharma companies name their assets

 
2015-11-12 08 Kirsten Messmer and Charity Metz Schuller

Senior RA Specialist, Regulatory Intelligence Solutions; and Director, Regulatory Affairs, PPDI

Regulatory Intelligence - Building Strategies for Drug Development  
2015-11-12 09 Larry Hofmann Managing Director, LMH Associates

pre-IND 12-step: Recipe for IND filing success

 
2015-11-12 10 Valerie Amspacher ORISE Fellow, FDA

Growing Pains - Making Pediatric clinical trials  better!

 
2015-11-12 11 Cynthia Nolte Director, Regulatory Affairs, ICON PLC

Integration of human factors engineering into medical device development

 
2015-11-12 13 Sandra Boyd Staff Associate, Biogen Idec

Split Personalities: Combination Products

 
2015-11-12 14 H Eiichi  Sengoku Manager, Diagnostics and Devices in Global Regulatory Affairs;  GlaxoSmithKline

Diagnostics across borders: Key differences of IVD regulations in the EU vs US

 
2015-11-12 15 Matt Medlin Manager, US Regulatory Affairs R&D Pipeline;  CHIESI USA, INC.

FDA’s Golden Tickets: Priority Review Vouchers for Rare Pediatric and Tropical Disease Drugs

 
2015-11-12 16 Jennifer Moen

Principal Clinical Research Scientist and Associate Director of Corporate Communications, Impact Pharmaceutical Services, Inc.

Medical Writing for Regulatory Affairs Professionals  
2015-10-15   Jay Campbell Executive Director, North Carolina Board of Pharmacy

Regulation of Pharmacy Compounding After NECC:  Opportunities and Challenges

 
2015-09-17   Mike Hinckle Partner at K&L Gates LLP

Expanded Access - Tough Choices and Unintended Consequences

 
2015-06-11   David Shoemaker Senior Vice President, R&D, Rho, Inc.

Regulatory Decision Making in Integrated Product Development 

 
2015-04-16   BJ Witkin Regulatory Publishing Manager, Impact Pharmaceutical Services

Electronic Publishing for Paper People: Things your publisher wishes she could tell you

 
2015-03-19   Mike Benecky Senior Director, Global Regulatory Affairs in Diagnostics, GlaxoSmithKline

Regulation of Companion Diagnostic Tests and FDA’s Proposed Regulatory Framework for Laboratory Developed Tests

 
2015-01-15   Erin O'Reilly

Associate Director Regulatory Affairs, Duke Translational Medicine Institute, Duke University

Mobile Apps as Medical Devices  
2014-11-13 01 Don Alexander

Practice Head and VP, Life Sciences (Carlyle Conlan)

Regulatory Affairs Profession  
2014-11-13 02 Celine Clive President (Polaris Compliance Consultants)

Risk based monitoring vs. Risk based auditing

 
2014-11-13 03 Jingwen Chen Global GMO Detection Lead (Syngenta Biotechnology)

Plant biotechnology product development, safety evaluation and regulatory approval

 
2014-11-13 04 I.M. Grossi (gina) Director of Toxicology (Chimerix)

GLP and Data Quality in Containment:  Studies Conducted Under The Animal Rule

 
2014-11-13 05 Denise Sturdy Regulatory Associate, Regulatory Intelligence (DCRI)

Sling back shoes and the changing landscape of clinical trial applications in the EU: what’s in store under Regulation (EU)536/2014

 
2014-11-13 06 Amy Blawas Associate Director of Pharmaceutical Development (Cato Research)

What's Mine is Mine, and What's Yours is Yours (DMFs)

 
2014-11-13 07 David Jensen Regulatory Associate, Investigational Applications (DCRI)

Unapproved Drugs Available at a Pharmacy Near You!

 
2014-11-13 08 Tammy Carrea President/CEO (RegMatters LLC)

FDA's recent changes to the substantial equivalence decision making process for 510(k)s

 
2014-11-13 09 Diya Abdeljabbar Senior Engineering Specialist, Upstream Process Analytics, Merck & Company Global Vaccine Supply & Regulation  
2014-11-13 10 BJ Witkin Regulatory Publishing Manager, Impact Pharmaceutical Services

BioCryst's NDA for Peramivir: regulatory & publishing challenges

 
2014-11-13 11 Emily Huddle

Regulatory Intelligence Executive - US (GlaxoSmithKline)

Regulatory Intelligence  
2014-11-13 12 Kevin Healy Director, Regulatory Affairs (Mallinckrodt Pharmaceuticals)

Breakthrough Therapies and Expedited Programs

 
2014-11-13 13 Susan Sisk Principal Consultant (spf Consulting)

Writing the CSR Synopsis: Reduce, Recycle, Reuse

 
2014-11-13 14 Nancy Chew

Principal Consultant (Regulatory Affairs North America)

Help! I need an IND!  
2014-11-13 15 Joseph Knight-McKenna

Director, Knowledge and Quality Management, Global Data and Safety Monitoring (Quintiles)

Inspection Readiness  
2014-10-16   Kamali Chance

Sr. Director; Head, Global Biosimilars Regulatory Strategy, Quintiles

Biosimilars in the US  
2014-09-18   Amanda Parrish and Erin O'Reilly

Associate Directors Regulatory Affairs, Duke Translational Medicine Institute, Duke University

Discussions with CDRH about Pre-Market Device Issues and clinical Research  
2014-05-01   Robert M. Califf, MD Vice Chancellor of Clinical and Translational Research, Director of the Duke Translational Medicine Institute (DTMI), and Professor of medicine in the Division of Cardiology at the Duke University Medical Center. Disrupting the Clinical Research Fabric in the US  
2014-04-17   Susan Watts

Director, Therapeutic Group, Global Regulatory Affairs at GlaxoSmithKline

PREA Compliance, PSPs under FDASIA

 
2014-03-20   Dana Minnick, Anita Woodring, and David Houck Drug Development Project Manager, Global Health Technologies, RTI International; Regulatory project leader, RTI International; and President, Pharmakey LLC Pre-IND Drug Development  
2014-02-16   Drusilla Scott Senior Vice-President, Regulatory Affairs,Cempra Pharmaceuticals

Follow the Yellow Brick Road - Special Regulatory Pathways for Drugs and Biologics in the US

 
2014-01-17   Larry Hofmann Managing Director, LMH Associates

The Pre-IND Program: 12 Steps to a successful IND filing

 
2013-11 01 Susan Watts  

New FDA Guidances for 2013

 
2013-11 02 Matt Medlin  

Sunshine Act Uncertainties

 
2013-11 03 Rachel Hardy  

From Crisis to Legislation to Regulation: The compounding pharmacy case

 
2013-11 04 Michael Hinkle  

Affordable Care Act’s Medical Device Excise Tax.

 
2013-11 05 Maria Oyaski  

Breakthrough Therapies - Are we fabulous enough yet?

 
2013-11 06 Lorna Dula  

ClinicalTrials.gov Results Reporting… It’s Not A Choice Anymore! 

 
2013-11 07 Linda Charles  

If I only knew then what I know now...or how to plan for your first CE mark EU Technical File. 

 
2013-11 08 Diane Wold  

Submission of Datasets using CDISC Standards

 
2013-11 09 Brooke Moody  

SOPs, Training and Auditing

 
2013-11 10 Don Alexander  

Regulatory Affairs Careers

 
2013-11 11 Cari Newton and Jamie Blackburn

Preparing for a Successful FDA Advisory Committee or Device Panel Meeting

 
2013-10-17   Allison L. St. John  

GLP and GMP in the Field of Biodefense

 
2013-09-19   Lisa Olson  

Electronic Records are Not My Responsibility - Guess Again!

 
2013-05-09   Brett Weed State Liaison, FDA-Atlanta District

Stories from the Sandbox: Regulatory Integration and Parallel Play

 
2013-04-18   Ken Edds  

What to Expect during an FDA Audit

 
2013-03-21   Tamara Pinkett  

A Statistician’s Perspective of Traditional Phase II and Phase III Drug Development

 
2013-02-21   Linda Charles and Maria Oyaski

Update on DSURs and approach for large and small companies

 
2012-11 01 Susan Zecchini  

 Advertising and promotion review. FDA Hot Buttons.

 
2012-11 02 Nancy Chew  

PreIND/IND Wonder Submissions: Your Bread and Butter.

 
2012-11 03 Michele Pruett  

Working in the Twilight Zone: "GMP" and quality elements for non-regulated R&D Labs

 
2012-11 04 Dana Minnick  

 ICH M7: Qualification of impurities and everything else in that goop you call a drug.

 
2012-11 06 Erin O'Reilly  

 ClinicalTrials.gov Registrations. Big Brother wants your data

 
2012-11 07 Celine Clive  

Risk Based Monitoring: Sanity returned or cheap trials?

 
2012-11 08 Drusilla Scott  

PDUFA V: Get with "The Program"!

 
2012-11 09 Aida Cancel  

 Clinical Trials and Product Registrations in Emerging Regions.

 
2012-11 10 Don Alexander  

Regulatory Affairs Careers. Get One.

 
2012-11 11 Ken Edds  

Hey! I'm talking here! Device Pre-Sumission discussions and meetings with FDA.

 
2012-10-04   Jason Rock Chief Technology Officer, GlobalSubmit Regulated Product Submissions (RPS)  
2012-09-13   RAPS Webinar  

Strategies for your Career:  Finding YOUR Pathway into Regulatory Affairs

 
2012-05-03   Pierre Leveau and Decebal Bora Head of the Quality Safety & Environment Unit at the European Directorate for the Quality of Medicines & HealthCare (EDQM); Director of Regulatory Affairs, ActoGeniX Biologicals in Europe, regulatory aspects and new developments  
2012-04-19   Drusilla Scott Senior Vice President of Regulatory Affairs, Cempra Pharmaceuticals What's New in Orphan Drugs  
2012-03-14   David Shoemaker Sr. Vice President, Research and Development, Rho, Inc.

PDUFA V: Possibilities and Practical Expectations

 
2012-02-16   Amy Kniefel Director Regulatory Affairs, AptivSolutions

eCTD Friendly Module 3: Considerations on How to Write an NDA Chemistry Section

 
2012-01-25   Neil Armstrong CEO MeddiQuest Limited

Recasting EU Medical Device Directives: Reasons, Rationale And Predictions

 
2011-11 01 Susan Watts and Don Kafader   Companion Diagnostics  
2011-11 02 Joe Knight-McKenna   Quality Risk Management  
2011-11 03 Karteek Sandadi  

Challenges in Migrating eCTDs from Multiple Tools and Format

 
2011-11 04 Nancy Chew  

Pre-IND/IND free-for-all

 
2011-11 05 Cari Newton 3D Communications

Advisory Committee Meetings: The Steps to a Successful FDA Advisory Committee

 
2011-11 06 Jeff Sorbel  

Adaptive Clinical Trial Designs

 
2011-11 07 Rebecca Sagosz  

Regulatory Intelligence

 
2011-11 08 Bob Kunka  

Pediatrics / consent

 
2011-11 09 Jeff Abolafia  

CDISC

 
2011-11 10 Maria Oyaski  

Special Protocol Assessment

 
2011-11 11 Ken Edds  

Medical Devices

 
2011-11 12 Don Alexander  

Regulatory Careers

 

 

 

ExComm MtgMin Feb2013

Annual Round Table 2012 Topics